Gilead's three-drug HIV regimen wins European panel approval

(Reuters) - Gilead Sciences Inc said on Friday its three-drug regimen to treat HIV infection was recommended for approval by a panel of the European Medicines Agency, paving the way for the biotech company to capture more sales in the multibillion-dollar market.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news